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receptor agonists
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Abstract: Marijuana is one of the most commonly used recreational drugs in the United States. As
marijuana is illegal in the majority of countries, the use of readily available and unregulated synthetic
cannabinoids (SCBs) has increased. Little is known about the potential adverse effects of SCBs especially in
regards to their nephrotoxicity. Case reports of acute kidney injury (AKI) from acute tubular injury secondary
to their use have been reported. However, the exact pathology, mechanism, and extent of renal injury remain
unknown. We report the first case of biopsy proven thrombotic microangiopathy (TMA) associated with
SCBs resulting in AKI. The patient suffered significant morbidity with loss of renal function eventually
requiring renal replacement therapy.
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Introduction
Synthetic cannabinoids (SCBs) are chemicals that produce
several marijuana-like effects in humans. In recent years,
they have become increasingly abused as they are cheap,
easily available on the internet, and are not detected by
routinely employed urine toxicology screening tests (1,2).
One in nine high school seniors admitted using SCBs in
2011, making it the 2nd most prevalent illicit drug after
marijuana (3). SCBs are dissolved in a volatile solvent and
mixed with an assortment of plant leaves, such as Indian
Warrior, Lion’s Ear, Dog Rose and/or Marshmallow leaves,
which are themselves purported to have psychotropic
effects upon smoking (4). Uneven distribution of SCBs to
the plant mixture can result in drug “hot spots”, making
dosing unpredictable and difficult, increasing the risk of
overdose (5). There are commercially available, quasi-legal,
unregulated ‘‘herbal incense’’ under names such as K2, K3,
Spice, Smoke and Dream, just to name a few (6).
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While usually labeled “not for human consumption”
distributors and consumers understand that these
products are to be used like marijuana primarily to attain a
subjectively pleasant cannabimimetic psychotropic effects.
This label has kept these products from being subjected
to the Federal Analogue Act of 1986. This transfers all
responsibility for the user’s safety from the manufacturers
and distributors to the consumer, who is often unaware of
the product’s potential danger (7). The most infamous of
which are JWH- 018, JWH-073, JWH-200, CP-47, 497
and cannabicyclohexanol (7). Reports of acute kidney injury
(AKI) attributed to it are on the rise but the underlying
pathophysiology is elusive (8). Previous reports of AKI have
shown diffuse patchy tubular injury favoring an ischemia
related injury (8). We are reporting the first case of a young
adult who presented with AKI after the use of SCBs and
found to have biopsy proven thrombotic microangiopathy
(TMA) as the major pathological pattern of the organ
injury.
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Case presentation
A 20-year-old man with no prior medical history presented
to the emergency department after 2 episodes of generalized
tonic-clonic seizures as witnessed by his mother. He
complained of nausea and vomiting prior to the seizure.
On arrival, he was conscious, then suffered from another
3-minute seizure episode. Intravenous levetiracetam
1,000 mg was given as initial treatment. Patient had no
past history of seizures. His initial blood pressure was
176/88 mmHg and heart rate was 104/minute. Physical
examination was otherwise unremarkable. He underwent
computed tomography of his head, which was negative for
bleeding or any other pathology.
Admission labs were consistent with anemia and AKI,
with hemoglobin of 8.3 mg/dL, hematocrit of 27.4 mg/dL,
and elevated serum creatinine of 3.2 mg/dL. He developed
thrombocytopenia (platelets trended down from
162,000/mm 3 on admission, to 147,000/mm 3 on day 1
and 124,000/mm 3 on day 2. On day 4 his serum lactate
dehydrogenase levels were elevated at 309 U/L increasing
to 530 U/L on day 10. Schistocytes were noted on
peripheral smear and serum haptoglobin level low, less than
8 mg/dL, consistent with intravascular hemolysis. Initial
urinalysis showed a specific gravity of 1.018, 3+ protein,
5–10 red blood cells per high power field, and RBC casts
on urine microscopy. Urine protein to creatinine ratio was
5.06 on spot testing. A routine drug screen was positive
for tetrahydrocannabinol. Serological investigation was
negative for antinuclear antibody (ANA), anti-neutrophil
cytoplasmic antibody (ANCA), anti-glomerular basement
membrane (GBM) antibody, hepatitis screens, and HIV
antibody screen.
Renal ultrasound was unremarkable. Since the patient
admitted to daily use of SCBs over the prior few weeks,
a sample was sent to the University of California in San
Francisco for toxicology analysis and showed the presence
of CP 47, CP 497 and Hebrew University (HU) 320. Due
to worsening renal function, a kidney biopsy was performed
and revealed thrombotic macroangiopathic lesions affecting
the glomeruli with acute tubular injury (Figure 1A-C). The
ADAMTS-13 (a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13) levels, which are
less than 10% in TTP, were within the normal range (67%
activity) which ruled out TTP. A clinical diagnosis of druginduced thrombotic microangiopathy (DITMA) with the
concern of an atypical hemolytic uremic syndrome (aHUS)
was suspected. Shiga toxin producing Escherichia coli
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testing was not performed, as the patient did not have any
diarrhea. The patient initially received plasmapheresis with
no response and was eventually started on hemodialysis.
The concern for aHUS possibly triggered by SCBs was
raised and treatment with complement blockade was offered
but the patient initially refused.
An endomyocardial biopsy was performed due
to significant decline of the left ventricular ejection
fraction to assess for possible need of simultaneous heart
transplantation (Figure 1D). Pathology was consistent
with TMA affecting small vessels. The patient eventually
underwent renal transplantation with eculizumab added to
his anti-rejection regimen. He did not consent to genetic
testing and the post-transplant serum creatinine level at
6 months was 1.4 mg/dL and the platelets count returned to
normal range, at 223,000/mm3.
Discussion
Thrombotic microangiopathies are life-threatening
ailments secondary to small vessel platelet microthrombi.
Clinical features include microangiopathic hemolytic
anemia (MAHA) with thrombocytopenia and AKI,
sometimes associated with neurologic abnormalities and
cardiac ischemia. The underlying pathophysiology of TMA
is endothelial damage of multiple etiologies. Etiology of
primary TMA include hereditary or acquired conditions,
such as thrombotic thrombocytopenic purpura (TTP),
shiga-toxin-producing Escherichia coli (STEC) hemolytic
uremic syndrome (HUS), DITMA, hereditary or acquired
complement-mediated TMA and rare hereditary disorders
of vitamin B12 metabolism.
DITMA is important to diagnose as it is a preventable
cause of TMA, generally managed first by withdrawing
the suspected drug. The diagnosis of DITMA is made
clinically with findings of MAHA and TMA associated
with concurrent drug exposure. However, management of
a patient with suspected DITMA may be challenging as
DITMA and other primary thrombotic microangiopathies
including TTP and complement-mediated TMA, have
a similar clinical presentation but require different
management modalities. A detailed clinical history is the
key to making the correct diagnosis.
Recently published systematic review included 78 drugs
known to cause TMA (9). We propose adding SCBs to this
list. Individual agents identified in the reported case include
CP 47, CP 497, and HU 320. Using the “Criteria for
Assessing Reports of Drug-Induced Thrombocytopenia and
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Figure 1 Renal and cardiac biopsy of patient. (A) Representative H&E stained image of a glomerulus and an adjacent arteriole showing
thrombotic microangiopathy (3 prong arrow). Glomerulus displays focal mesangial expansion with increase in reticulated matrix material
associated with partial endocapillary obliteration and focal double contouring of the capillary walls (arrow) (×100); (B) a trichrome stained
section reveals marked tubular injury possibly secondary to marked vascular and microvascular thrombotic microangiopathy (×50); (C)
representative electron microscopic image of a glomerular capillary showing mesangial expansion with increase in granulated mesangial
matrix associated with circumferential mesangial interposition and double contouring of capillary walls (arrow) (×5,000); (D) representative
cardiac biopsy showing marked edematous thickening and obliteration of 2 inter myocytic arterioles (thick arrows). A normally patent
arteriole is also present (thin arrow mid bottom area).

Table 1 Pathogenesis of synthetic cannabinoid induced TMA
Mechanism

Pros

Cons

Complement Low suspicion for TTP (ADAMTS No genetic
dysfunction 67%); low suspicion for HUS (no testing
diarrhea or GI symptoms)
available
Drug induced Low suspicion for TTP (ADAMTS Definite criteria
TMA
67%); low suspicion for HUS (no not met
diarrhea or GI symptoms)

Levels of Evidence for a Causal Relation between the Drug
and Thrombocytopenia” in our patient, a probable level of
causality can be ascertained as described (10). These include
that the suspected drug was taken before thrombocytopenia
occurred and recovery from thrombocytopenia was
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complete and sustained after the drug was discontinued.
Moreover, the suspected drug should be the only drug
taken before the onset of thrombocytopenia, or other drugs
were continued or reintroduced with a sustained normal
platelet count. Additionally, to the extent possible with
secondary documentation, all other potential causes of
thrombocytopenia were reasonably excluded (10). This is
further presented in Table 1.
The exact mechanism of drug induced TMA remains
elusive but some reports suggest an idiosyncratic, acute
immunologic reaction whereas others suggest a direct toxic
effect, which may be either acute dose-related toxicity or
chronic dose and duration-dependent toxicity (11). Some
patients had severe kidney injury and were described
as having HUS; others had minimal kidney injury. It is
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possible that patients with severe HUS presentation may
have an underlying complement dysregulation.
Inherited and acquired complement alternative pathway
dysregulation, is related to various renal diseases by
defective complement control, leading to the deposition of
activated products, known as C3 glomerulopathies. Current
modalities of treatment available for complement regulation
include blockade with the anti-C5 monoclonal antibody
eculizumab or by plasma substitution with success seen in
several cases (12).
The agents included in SCBs may provide the second
hit by unmasking the abnormality resulting in endothelial
damage. Our patient failed to respond with plasmapheresis
which makes it more likely that TMA was caused either by
the direct toxic effect of these substances or by unmasking
an underlying complement dysregulation.
There are various reports of kidney injury secondary
to SCB related with acute tubular injury or allergic
interstitial nephritis as the predominant clinical diagnosis,
with no reported cases of biopsy proven TMA. There
were four cases reported in which AKI was associated
with synthetic cannabinoids with acute tubular injury as
predominant pathology in renal biopsy (13). The Center for
Disease Control and Prevention reported 16 cases of SCB
induced AKI in multiple states with acute tubular injury
demonstrated on 6 renal biopsies out of 8 performed, and
acute interstitial nephritis found in 3 of 8 biopsies (14).
We are reporting for the first time SCB induced acute
injury associated with biopsy proven TMA/vasculopathy in
both kidney and heart. Arterioles and arteries of all sizes up
to arcuate size were affected. In view of the marked vascular
involvement including those of larger size, it was concluded
that acute tubular injury was most likely secondary to severe
vasculopathy. TMA may be more prevalent in SCBs but
perhaps remain underreported due to the lack of renal
biopsy in the majority of such cases.
Cannabinoid 1 and cannabinoid 2 receptors are present
in almost all cell types in the kidney and play an important
role in regulating normal renal physiology via the
endocannabinoid system (15). Changes in these receptors
are seen in pathological states like diabetic nephropathy,
which causes the cannabinoid 2 receptor downregulation.
Cannabinoid 1 receptor upregulation has been documented
in IgA nephropathy, in acute interstitial fibrosis, and in
mesangial fibrosis (16). One may postulate a cannabinoid
receptor mediated injury to endothelial cells and/or
podocytes, serves as an initial insult interfering with vascular
endothelial growth factor receptor, leading to thrombosis
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and TMA.
Conclusions
The reported case represents the first biopsy-proven TMA
secondary to SCB, not previously reported in English
literature. We recommend adding SCB to the list of drugs
associated with DITMAs. The implication that SCBs has
deleterious effects, including DITMA necessitates further
regulation on the manufacturing and selling of SCBs.
Clinicians should be aware of these effects of SCBs as the
drug has become more popular and these have not been
reported with marijuana use. Further reporting and research
of the SCBs and marijuana effects could better characterize
SCBs association with renal injury.
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